FDA Clears Cingulate to File NDA for CTx-1301 in the Treatment of ADHD

The company has announced plans to submit the NDA in the first half of 2025.

Related Keywords

United States ,American ,Ann Childress ,Shanej Schaffer ,American Professional Society ,Drug Administration ,Behavior Medicine Inc ,Cingulate Inc ,New Drug Application ,Related Disorders ,Annual Meeting ,Permanent Product Measure ,